Zheng Chang1, Patrick D Quinn2, Kwan Hur3, Robert D Gibbons3, Arvid Sjölander4, Henrik Larsson5, Brian M D'Onofrio6. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden2Center for Health Statistics, The University of Chicago, Chicago, Illinois. 2. Center for Health Statistics, The University of Chicago, Chicago, Illinois3Department of Psychological and Brain Sciences, Indiana University, Bloomington. 3. Center for Health Statistics, The University of Chicago, Chicago, Illinois. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden4School of Medical Sciences, Örebro University, Örebro, Sweden. 6. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden3Department of Psychological and Brain Sciences, Indiana University, Bloomington.
Abstract
Importance: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. Objective: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. Design, Setting, and Participants: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. Exposures: Dispensed prescription of ADHD medications. Main Outcomes and Measures: Emergency department visits for MVCs. Results: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. Conclusions and Relevance: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.
Importance: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. Objective: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. Design, Setting, and Participants: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. Exposures: Dispensed prescription of ADHD medications. Main Outcomes and Measures: Emergency department visits for MVCs. Results: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. Conclusions and Relevance: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.
Authors: Jack E Gibson; Richard B Hubbard; Christopher J P Smith; Laila J Tata; John R Britton; Andrew W Fogarty Journal: Am J Epidemiol Date: 2009-01-30 Impact factor: 4.897
Authors: Gregory A Fabiano; Nicole K Schatz; Karen L Morris; Michael T Willoughby; Rebecca K Vujnovic; Kevin F Hulme; Jessica Riordan; Marlana Howard; Dwight Hennessy; Kemper Lewis; Larry Hawk; Amanda Wylie; William E Pelham Journal: J Consult Clin Psychol Date: 2016-09-12
Authors: Zheng Chang; Paul Lichtenstein; Brian M D'Onofrio; Arvid Sjölander; Henrik Larsson Journal: JAMA Psychiatry Date: 2014-03 Impact factor: 21.596
Authors: Zheng Chang; Patrick D Quinn; Lauren O'Reilly; Arvid Sjölander; Kwan Hur; Robert Gibbons; Henrik Larsson; Brian M D'Onofrio Journal: Biol Psychiatry Date: 2019-12-13 Impact factor: 13.382
Authors: Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson Journal: Biol Psychiatry Date: 2019-04-17 Impact factor: 13.382
Authors: Allison E Curry; Benjamin E Yerys; Kristina B Metzger; Meghan E Carey; Thomas J Power Journal: Pediatrics Date: 2019-05-20 Impact factor: 7.124
Authors: Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen Journal: Pediatrics Date: 2019-10 Impact factor: 7.124
Authors: Kenneth K C Man; Patrick Ip; Esther W Chan; Siew-Ling Law; Miriam T Y Leung; Evelyn X Y Ma; Wan-Ting Quek; Ian C K Wong Journal: CNS Drugs Date: 2017-12 Impact factor: 5.749
Authors: Joseph Biederman; Maura DiSalvo; Ronna Fried; K Yvonne Woodworth; Itai Biederman; Stephen V Faraone Journal: J Adolesc Health Date: 2019-07-23 Impact factor: 5.012
Authors: Paula A Aduen; Michael J Kofler; Dustin E Sarver; Erica L Wells; Elia F Soto; Daniel J Cox Journal: J Psychiatr Res Date: 2018-03-06 Impact factor: 4.791